Core Viewpoint - *ST Jingfeng is forecasting a significant net loss for the year 2025, with expected net profit attributable to shareholders ranging from -90 million to -60 million yuan, and a net profit excluding non-recurring items expected to be between -64 million and -43 million yuan [1] Group 1: Financial Performance - The company attributes the anticipated losses for 2025 to a decline in sales prices of its main products due to pharmaceutical industry policy changes, resulting in continued operational losses [1] - In contrast, the company reported a turnaround in 2024, achieving profitability due to a waiver from bondholders on 110 million yuan of principal and all related fees for the "16 Jingfeng 01" bonds, which contributed 266 million yuan to investment income [1] Group 2: Market Conditions - The sales of the company's main products have not shown a significant recovery, which is a contributing factor to the expected losses in 2025 [1]